Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

The Haemophilia Society led campaign for full access to recombinant Factor 8.

  • Read more about The Haemophilia Society led campaign for full access to recombinant Factor 8.

NICE recommended alpha interferon and ribavirin combination therapy for the treatment of moderate to severe Hepatitis C

  • Read more about NICE recommended alpha interferon and ribavirin combination therapy for the treatment of moderate to severe Hepatitis C

Hepatitis C Strategy for England was published.

  • Read more about Hepatitis C Strategy for England was published.

Ministers in England accepted recommendation for recombinant to be made available for all adult haemophilia patients on a phased basis over a 4-5 year period starting in 2002-03.

  • Read more about Ministers in England accepted recommendation for recombinant to be made available for all adult haemophilia patients on a phased basis over a 4-5 year period starting in 2002-03.

Scotland and Northern Ireland confirmed that all haemophilia patients would be placed on recombinant treatment.

  • Read more about Scotland and Northern Ireland confirmed that all haemophilia patients would be placed on recombinant treatment.

The Secretary of State for Health announced that recombinant products were to be made available for all children under 16 and previously untreated patients in England.

  • Read more about The Secretary of State for Health announced that recombinant products were to be made available for all children under 16 and previously untreated patients in England.

Wales adopted policy of recombinant Factor 8 for all Haemophilia A patients.

  • Read more about Wales adopted policy of recombinant Factor 8 for all Haemophilia A patients.

UKHCDO confirmed recombinant Factor 8 as the safest product available for the treatment of people with bleeding disorders.

  • Read more about UKHCDO confirmed recombinant Factor 8 as the safest product available for the treatment of people with bleeding disorders.

Patients reported difficulties accessing alpha interferon treatment.

  • Read more about Patients reported difficulties accessing alpha interferon treatment.

Alpha interferon was licensed for the treatment of Hepatitis C in the UK.

  • Read more about Alpha interferon was licensed for the treatment of Hepatitis C in the UK.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 778
  • Page 779
  • Page 780
  • Page 781
  • Current page 782
  • Page 783
  • Page 784
  • Page 785
  • Page 786
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.